Podcast Episodes
Back to Search
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative f…
8 years, 2 months ago
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
8 years, 2 months ago
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explain…
8 years, 2 months ago
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug a…
8 years, 3 months ago
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trad…
8 years, 3 months ago
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca exp…
8 years, 3 months ago
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?
8 years, 3 months ago
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepre…
8 years, 4 months ago
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.
8 years, 4 months ago
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?
8 years, 4 months ago